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Abstract 
Circulating miRNAs have been shown as promising biomarkers for various pathologic con-
ditions. The aim of this study was to clarify that circulating miR-1 and miR-126 in human 
plasma might be useful as biomarkers in acute myocardial infarction (AMI). In our study, after 
pre-test, two candidate miRNAs were detected by using real-time RT-PCR. Cardiac troponin 
I (cTnI) concentrations were measured by ELISA assay in plasma from patients with AMI 
(n=17) and healthy subjects (n=25), simultaneously. Increased miR-1 and decreased miR-126 
in plasma from patients with AMI after the onset of symptoms compared with healthy subjects 
were found. A remarkable finding in this study is that miR-1, miR-126 and cTnI expression 
levels exhibited the same trend. Our results suggest that the plasma concentrations of miR-1 
and miR-126 may be useful indicators for AMI. 
Key words: circulating miRNA; biomarker; AMI. 
Introduction 
MicroRNAs  (miRNAs)  are  a  relatively  novel 
class of endogenous, non-protein coding small RNA 
molecules  that  can  regulate  hundreds  of  genes 
through binding to the 3’ UTR of target mRNAs [1-3]. 
MiRNAs have been proven to play important roles in 
self-renewal,  cellular  development,  differentiation, 
proliferation  and  apoptosis  [4,  5].  Mature  miRNAs 
bind to specific regions of mRNA targets by a mecha-
nism that is not completely understood, resulting in 
translational repression or mRNA degradation [6-9].  
The  human  genome  encodes  more  than  1,000 
miRNAs with tissue or cell type specific expressions 
[10-13]. Studies have shown that miRNAs have been 
observed in a wide range of human diseases, includ-
ing  autoimmune,  inflammatory,  neurodegenerative 
and  cardiovascular  diseases  [14,  15].  There  are 
mounting  evidences  showing  that  cardiac-specific 
miRNAs,  miR-1,  miR-133a/b  and  miR-208,  are  in-
volved in heart development and cardiovascular dis-
eases, including acute myocardial infarction (AMI) in 
experimental animals [16]. Recent studies have shown 
that some miRNAs are present in the systemic circu-
lation, both in humans and animals, and are associ-
ated  with  exosomes  and  microparticles  [17-20].  The 
levels  of  some  circulating  miRNAs  have  been  re-
ported  to  be  differentially  expressed  during  preg-
nancy and in the presence of a variety of cancers or 
cardiovascular diseases. 
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High  mortality  and  morbidity  is  common  in 
AMI. Some biomarkers have been applied in diagno-
sis of AMI; for example, cardiac troponin I (cTnI), MB 
and so on. New approaches that can improve current 
diagnosis for AMI are still lacking.  
However,  the  expression  and  possible  roles  of 
miRNAs in AMI are less well studied. Cardiac injury, 
which occurs after AMI increases the circulating lev-
els  of  several  myocardial-derived  miRs  (eg,  miR-1, 
miR-133,  miR-499,  miR-208),  whereas  patients  with 
coronary artery disease or diabetes showed reduced 
levels of endothelial-enriched miRs, such as miR-126 
[21]. In the present study, we assessed the hypothesis 
that miR-1 and miR-126 might be useful for identify-
ing  and  evaluating  AMI.  Our  aim  was  to  look  for 
miRNA-based modulation of gene expression in AMI. 
Materials and Methods 
Blood Samples     
This  study  was  supported  by  the  Ethics  Com-
mittee of Tongji Hospital, and was performed in ac-
cordance  with  the  principles  of  the  Declaration  of 
Helsinki.  After  gaining  their  written  informed  con-
sents,  we  gathered  blood  samples  from  17  patients 
and  25  healthy  adults  at  Tongji  Hospital  between 
October  2009  and  May  2010.  AMI  was  diagnosed 
based on combination of several criteria: 1) ischemic 
symptoms; 2) creatine kinase-MB (CK-MB); 3) patho-
logical Q wave; 4) increased cTnI; and 5) ST-segment 
elevation or depression [22]. In addition, 25 healthy 
adult  volunteers  (normal  electrocardiogram  and  no 
history  of cardiovascular diseases) were enrolled  in 
this study. The blood samples of patients with AMI 
were acquired at 4h (± 30min), 8h (± 30min), 12h (± 
30min), 24h (± 30min), 48h (± 30min), 72h (± 30min) 
and 1w (± 60min) after the onset of symptoms. Plasma 
was isolated by centrifugation and conserved at -80°C 
until purification. 
RNA Purification 
Total  RNA  was  extracted  from  plasma  with 
TRIzol LS Reagent as described previously [23].  
Plasma cardiac troponin I determine 
Plasma  cTnI  concentrations  were  measured  by 
ELISA assay according to the manufacturer’s protocol 
(Abnova, Taiwan). 
MiRNA qRT-PCR 
Two μg of total RNA were reverse-transcribed 
using  Transcript  First-strand  cDNA  Synthesis  Su-
perMix (TransGen Biotech, Beijing, China) in accord-
ance to the manufacturer’s protocol. In short, the 50 
uL reactions were incubated for 60 min at 42°C, 10 
min at 70°C, and then stored at 4°C. 
qRT-PCR were analyzed using the Bulge-Loop™ 
miRNA  qRT-PCR  Detection  Kit  (Ribobio  Co., 
Guangzhou,  China)  and  TransStartTM Green  qPCR 
SuperMix  (TransGen  Biotech,  Beijing,  China)  in  ac-
cordance with the manufacturer’s protocol with the 
Rotor-Gene  6000  system  (Corbett  Life  Science, 
QIAGEN,  Hilden,  Germany).  Briefly,  the  reactions 
were incubated at 95°C for 30s, followed by 40 cycles 
of 95°C for 30s, 60°C for 20s, 70°C for 1s. The relative 
expression level for each miRNA was computed using 
the comparative CT method. It is important to note 
that to control for possible diversity in the amount of 
starting RNA, miRNA expression was normalized to 
small nucleolar RNA U6.  
Statistical analysis 
A  widely  used  method  to  present  relative  ex-
pression of miRNA is the 2-ΔΔct method. Relative ex-
pression of miRNA presents the data of the miRNA of 
interest  (CtmiRNA  of  interest)  relative  to  internal  control 
gene  (Ctinternal  control  miRNA),  termed  Δct.  Results  are 
calculated as Δct± standard deviation (SD). Different 
groups  of  AMI  patients  and  healthy  adults  were 
compared with Δct±SD of the control group (healthy 
adults)  and  tested  for  statistical  significance.  When 
the differences in Δct±SD of the tested groups reached 
or were below p = 0.05, the difference in miRNA ex-
pression was considered statistically significant. The 
data were presented as fold change graphically. Fold 
change of the tested group is calculated relative to the 
control group (healthy adults) using the 2-ΔΔct equa-
tion. 
All  values  of  miRNAs  are  expressed  as 
mean±SD.  Comparisons  of  parameters  among  ≥  3 
groups  were  analyzed  by  repeated-measures 
ANOVA.  Independent-sample  T  test  was  used  for 
2-group  comparisons.  For  categorical  variables, 
Chi-Square  test  was  used.  Time-course  trends  of 
miRNAs  and  cTnI  were  analyzed  by  repeat-
ed-measures  ANOVA.  Differences  were  considered 
statistically significant at a value of P<0.05. 
A score (miRNA-score) was defined as the level 
of miR-1 and miR-126 in the AMI group as compared 
with the control group. The miR-1 and miR-126-score 
of each sample was calculated as the sum of the in-
verted-normalized  signals  of  the  miR-1  and 
miR-126-scores and adjusted by subtracting a constant 
(the minimal score), so that the range of scores starts 
at 0 [24]. 
For all statistical analyses, the statistical software 
SPSS 13.0 for Windows was used. Int. J. Biol. Sci. 2012, 8 
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Results 
Statistical analysis of patients’ characteristics 
Among 17 patients with AMI, 13 were males and 
4 females; their age ranged between 40 and 70 years 
(mean  53±12.5).  All  patients  had  a  transmural  MI. 
There were no statistical differences between the con-
trol group and the AMI patients for any of the con-
sidered variables such as LDL cholesterol, total cho-
lesterol,  total  triglycerides,  HDL  cholesterol,  white 
blood  cell  count,  systolic  blood  pressure,  diastolic 
blood pressure, creatinine and history of diabetes and 
smoking  status  were  recorded  respectively.  Details 
were shown in Table 1. 
 
Table 1. Clinical characteristics of patients. 
Characteristics  Total pa-
tients 
(n=42) 
AMI (n=17 
) 
Healthy 
adults 
(n=25) 
p 
Age (years)  52.5±11  53±12.5  51±12.3  0.42 
Male/female (n/n)  31/11  13/4  18/7  0.75 
WBC ( *109 /L)  7.3±1.8.0  8.2.0±2.4  6.1±1.35  0.083  
HDL C (mmol/L)  1.14±0.25  1.08±0.23  1.23±0.28  0.56 
TG (mmol/L)  1.52 ±1.2  1.36±0.73  1.48±1.37  0.76 
Hyperlipidaemia, n 
(%) 
4 (10%)  2 (12%)  2 (8%)  0.35 
Cr (umol/L)  66±30.5  85±51  54±15  0.46 
SBP (mmHg)  126. ±14  138±22  120 ±16  0.82 
DBP (mmHg)  82 ±14  84±16  76±12  0.46 
Current smoking, n 
(%) 
23 (63 %)  12 (75%)  11 (55%)  0.089 
Fasting glucose 
(mmol/L) 
5.46±1.53  6.07±1.23  5.23±1.63  0.5 
TC (mmol/L)  4.32±0.65  4.02±0.  4.15±0.650.82 0.8 
LDL C (mmol/L)  2.27±0.57  2.58±0.6  2.23±0.54  0.6 
DM, n (%)  3 (7.%)  2 (12%)  1 (4%)  0.36 
Hypertension, n (%)  16 (38 %)  8 (50%)  8 (30%)  0.324 
DM, diabetes mellitus; TC, total cholesterol; HDL C, high-density 
lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; LDL C, low-density lipoprotein cholesterol; WBC, 
white blood cell; Cr, creatinine. P, comparison between patients 
with healthy adults. TG, total triglyceride. 
MicroRNAs plasma levels in AMI and healthy 
adult 
Using qRT-PCR, we analyzed the expression of 
two miRNAs in AMI patients and in healthy adults. 
The results were summarized in Table 2 and Figure 1. 
The data showed that plasma levels of miR-1 exhib-
ited 3.63 (± 0.94) fold, 15.87 (± 4.5) fold, 5.9 (± 1.03) 
fold, 2.37 (± 0.50) fold, 4.9 (± 1.34) fold, 4.3 (± 1.2) fold 
and 2.38 (± 0.58) fold increase at 4h (± 30min), 8h (± 
30min), 12h (± 30min), 24h (± 30min), 48h (± 30min), 
72h (± 30min) and 1w (± 60min), respectively (Table 2 
and  Fig.  1A).  miR-126  levels  in  AMI  patients  were 
78%, 48%, 64%, 90%, 58%, 82% and 93% lower than in 
healthy controls at 4h (± 30min), 8h (± 30min), 12h (± 
30min), 24h (± 30min), 48h (± 30min), 72h (± 30min) 
and 1w (± 60min) (Table 2 and Fig. 1B), respectively. 
Then, circulating miR-1 and miR-126 expression time 
courses  were  analyzed  by  repeated-measures 
ANOVA.  As  shown  in  Fig.  1,  miR-1  and  miR-126 
plasma levels in AMI at each time point were com-
pared. MiR-1 expression was obviously up-regulated 
at 8h (± 30min) compared with other time points (Fig. 
1A), while miR-126 concentration was clearly down-
regulated  at  24h  (±  30min)  and  1w  (±  60min)  com-
pared with other time points (Fig. 1B).  
Simultaneous microRNAs and cTnI plasma 
levels determination in AMI patients 
Plasma  cTnI  concentrations  were  measured  by 
ELISA assay according to the manufacturer’s proto-
col. In 17 patients, miRNAs and cTnI were measured 
from  the  same  plasma  samples.  Compared  with 
healthy adults, cTnI peak increase of 2584 (± 646) fold 
was achieved at 8h. cTnI increased 2555 (± 655) fold, 
1748 (± 437) fold, 1919 (± 329) fold, 892 (± 244) fold, 
611 (± 44) fold and 11.3 (± 1.3) fold at 4h, 12h, 24h, 48h, 
72h  and  1w,  respectively  (Fig.  1C  and  1D).  Mean-
while, miR-1, miR-126 and cTnI time courses exhib-
ited  the  same  trends  in  these  patients,  by  repeat-
ed-measures ANOVA analysis. Importantly, no  sig-
nificant  interaction  effects  were  found  in  the  time 
course between miRNAs and cTnI  (Fig. 1C and 1D). 
Table 2.
 
MiR-126 and miR-1 in human AMI groups and healthy adults. 
    MI (4h)  MI (8h)  MI (12h)  MI (24h)  MI (48h)  MI (72h)  MI (1w)  healthy adult 
miR-126  (Δct±SD)  2.61±0.5  1.35±0.33  1.85±0.27  3.66±0.82  1.64±0.34  2.89±0.59  4.23±0.38  0.40±0.12 
p value    0.01  0.02  0.04  0.01  0.02  0.01  0.01   
AUC    0.86  0.87  0.88  0.87  0.84  0.83  0.78   
miR-1  (Δct±SD)  8.14±2.11  6.0±1.72  7.4±1.3  8.76±1.83  7.7 ±2.1  7.9 ±2.2  8.76±2.15  10.0±2.12 
p value    0.001  0.02  0.04  0.03  0.003  0.01  0.02   
AUC    0.92  0.90  0.94  0.92  0.96  0.90  0.76   
Δct value of miR-126 and miR-1 in human AMI groups and healthy adults is presented as an average group Δct±SD. Corresponding p values 
were calculated using independent-samples T test, and missing p values represent non significant Δct changes. AUC indicates the area under 
the receiver operating characteristic (ROC) curve for the differentiation between AMI and control groups. Int. J. Biol. Sci. 2012, 8 
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Figure 1. MicroRNAs expression of plasma in patients with AMI. MicroRNAs plasma levels in patients with AMI using real-time 
PCR assays. Plasma samples were collected at 4h (± 30min), 8h (± 30min), 12h (± 30min), 24h (± 30min), 48h (± 30min), 72h (± 30min) 
and 1w (± 60min) after the onset of symptoms. (A) Expression level of miR-1 at different time points; (B) Expression level of miR-126 at 
different time points; Time courses of circulating miRNA and cTnI from the same plasma samples in patients with AMI and healthy control 
subjects; (C) Circulating miR-1 expression at different time points; (D) Circulating miR-126 expression in different time points; Values 
show fold changes of each microRNA vs. its level in the control group, arbitrarily set at 1 as indicated by CTRL, and fold changes of cTnI 
vs. its level in control group, arbitrarily set at 0.8 as indicated by the CTRL. The data were normalized to the peak level for each microRNA 
and cTnI achieved in each patient and the time of the peak-fold increase vs. results are reported as mean±SD (*, p< 0.05; **, p≤0.01). 
 
Specificity and sensitivity of miR-1 and 
miR-126 
Since the detected levels of miR-1 and miR-126 in 
plasma may be affected by both technical and biolog-
ical variation, we combined the levels of miR-1 and 
miR-126 into a single score to provide an improved 
signal  to  noise  ratio.  The  miR-1-score  and 
miR-126-score stand for the plasma levels of the miR-1 
and  miR-126  with  P<0.0001  for  the  comparison  be-
tween AMI and control group, was calculated as de-
scribed  in  the  methods  section.  The  miR-1  and 
miR-126-scores  allowed  a  significant  separation  be-
tween  the  AMI  and  control  groups  (P  =  1e-7).  The 
median score of miR-1 is 2.16, 2.55, 2.85, 2.58, 2.52 and 
2.10 in the AMI group. It is 1.04, 1.39, 1.25, 1.1, 0.96 
and 1.08, respectively, in the control group at 4h, 8h, 
12h, 24h, 48h and 72h (Figure 2). The ability of the 
miR-1-score to differentiate the AMI group from the 
control group is demonstrated by the ROC curve with 
an AUC of 0.92, 0.90, 0.94, 0.92, 0.96 and 0.90 (Figure 3 
and Table 2). By using a threshold score of 1.57, 2.03, 
2.26, 1.47, 1.83 and 1.74 above which patients are pre-
dicted  to  belong  to  the  AMI  group,  we  achieved  a 
sensitivity of 93%, 93%, 94%, 93%, 93% and 90% and a 
speciﬁcity of 90%, 90%, 93%, 90%, 90% and 90%, re-
spectively, for the identiﬁcation of AMI patients. The 
median score of miR-126 is 2.51, 2.55, 2.5 2.6, 2.4 and 
2.2 in the AMI group. It is 1.31, 1.31, 1.30, 1.35, 1.21 
and 1.20 in the control group at 4h, 8h, 12h, 24h, 48h 
and  72h  (Figure  4).  The  ROC  curve  of  miR-126 
showed moderate ability to distinguish between the 
AMI group and the healthy control group at 4h, 8h, 
12h, 24h, 48h and 72h with an AUC of 0.86, 0.87, 0.88, 
0.87, 0.84 and 0.83 (Figure 5 and Table 2), respectively. 
Using a threshold score of 1.6, 1.59, 1.88, 1.7, 1.2 and 
1.25 in the AMI group, we gained a speciﬁcity of 78%, 
84%, 88%, 77%, 80% and 70% and a sensitivity of 81%, 
81%,  81%,  81%,  81%  and  81%,  respectively,  for  the 
diagnosis of AMI in patients. Int. J. Biol. Sci. 2012, 8 
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Figure 2. Plasma miR-1-score in AMI groups and control group. Differences between various time points after the onset of AMI 
and control groups using the miR-1-score are presented. (A) 4h; (B) 8h; (C) 12h; (D) 24h; (E) 48h; (F) 72h. 
 
 
Figure 3. Plasma miR-1 is significantly associated with AMI. Receiver operating characteristic (ROC) curve for miR-1-score 
discriminates between various time points after the onset of AMI and control groups using the miR-1-score. (A) 4h; (B) 8h; (C) 12h; (D) 
24h; (E) 48h; (F) 72h.  Int. J. Biol. Sci. 2012, 8 
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Figure 4. Plasma miR-126-score in AMI groups and control group. Plasma miR-126-score is shown between AMI groups and 
control group at 4h, 8h, 12h, 24h, 48h and 72h. Lines show median values, which were 2.51, 2.55, 2.5, 2.6, 2.4 and 2.2 in the AMI group and 
1.31, 1.31, 1.3, 1.35, 1.21 and 1.2 in the control group (P = 1e-7) (A, B, C, D, E and F). 
 
 
Figure 5. Plasma miR-126 is strongly associated with AMI. Receiver operating characteristic (ROC) curve analysis of the diag-
nostic value of circulating miR-126 for AMI at 4h, 8h, 12h, 24h, 48h and 72h. The areas under the curve (AUC) are 0.86, 0.87, 0.88, 0.87, 
0.84 and 0.83 (A, B, C, D, E and F). Int. J. Biol. Sci. 2012, 8 
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Discussion 
MiRNA  regulates  gene  expression  by  binding 
and  modulating  the  translation  of  specific  miRNAs 
[25-28]. In recent years, tremendous efforts have been 
made to use a miRNA microarray screening approach 
to address the miRNA expression profiling in infarted 
hearts from animal models [28-30]. Recent evidences 
suggested that miRNAs are excellent promising dis-
ease biomarkers [31-33]. MiRNAs have been consist-
ently  detected  in  serum,  plasma  and  other  bodily 
ﬂuids and speciﬁc miRNA patterns have been associ-
ated with pregnancy and with certain diseases [34-36]. 
MiRNAs have been shown to play important roles in 
development, stress responses, angiogenesis and on-
cogenesis. Accumulating evidence also points to im-
portant roles of miRNAs in the cardiovascular system 
[8, 37]. However, the role of miRNA in AMI is just 
emerging. 
In  this  study,  we  reported  the  circulating  ex-
pressions of miR-1 and miR-126 in AMI patients, in 
comparison  to  healthy  adults.  The  most  significant 
finding  was  that  plasma  levels  of  miR-126  were 
down-regulated in acute myocardial infarction at 4h 
(± 30min), 8h (± 30min), 12h (± 30min), 24h (± 30min), 
48h (± 30min), 72h (± 30min) and 1w (± 60min) after 
the onset of AMI symptoms. Importantly, miR-1 was 
up-regulated  at  4h  (±  30min),  8h  (±  30min),  12h  (± 
30min), 24h (± 30min), 48h (± 30min), 72h (± 30min) 
and 1w (± 60min) after the onset of AMI symptoms. A 
remarkable  finding  in  this  study  is  that  miR-1, 
miR-126 and cTnI exhibited the same trends, howev-
er, with no significant interaction effects. The plasma 
concentration of miR-1 and miR-126 showed a good 
correlation with the plasma concentration of cTnI, a 
classic biomarker of myocardial injury. The validity of 
circulating cTnI as a marker of myocardial injury has 
been reported [36]. In our study, the plasma concen-
trations of cTnI and miR-1, miR-126 were highly cor-
related and exhibited similar time courses. Using the 
levels of the miR-1 and miR-126, we were able to de-
fine a score with a high sensitivity and speciﬁcity for 
the detection of AMI patients at 4h, 8h, 12h, 24h and 
72h  relative  to  control  group.  Furthermore,  to  look 
into  the  possible  mechanisms  of  miR-1/miR-126  in 
AMI,  computational  predictions  as  described  at 
MICROCOSM,  miRanda,  TargetScan  and  Pic  Tar 
were  employed.  These  analyses  yielded  901/937, 
7204/815,  790/25  and  535/21  potential  candidates. 
Some  of  them  were  reported  to  be  associated  with 
coronary  diseases,  such  as  GJA1,  KCNJ2  [38], 
tanshinone IIA [39], LRP6 [40]. Taken together, our 
results clearly support that miR-1 and miR-126 may 
be useful potential biomarker of AMI. 
To avoid possible confounders derived from pa-
tient selection, age, gender, total triglyceride, creati-
nine, HDL cholesterol, LDL cholesterol, white blood 
cell  count,  total  cholesterol,  systolic  blood  pressure, 
diastolic  blood  pressure,  history  of  diabetes  and 
smoking status, all these were recorded in our study. 
Statistical analyses showed that they have no influ-
ence  on  plasma  miRNA  levels.  This  suggested  that 
miR-1  and  miR-126  were  potential  biomarkers  for 
certain diseases.  
The  present  study  confirmed  that  miR-1  and 
miR-126  can  be  used  as  biomarkers  of  AMI  in  hu-
mans.  The  next  question  is  whether  assessment  of 
plasma  miR-1  and  miR-126  concentration  has  any 
clinical significance. MiRNAs might be an especially 
rich  source  of  diagnostic,  prognostic  and  predictive 
information as biomarkers in AMI patients [41]. 
It should be noted that the present study of cir-
culating miR-1 and miR-126 as potential biomarkers 
for AMI was conducted in a relatively small sample 
size  and  future  evaluation  in  larger  clinical  studies 
will be needed to confirm the utility as a biomarker. 
Nonetheless, our study provides a solid basis to iden-
tify and develop miR-1 and miR-126 as a novel class 
of blood-based biomarkers for AMI in the future. 
In  summary,  we  found  that  circulating  miR-1 
and miR-126 of patients with AMI were significantly 
changed in a time dependent manner. This suggests 
that miR-1 and miR-126 have potential utility as novel 
potential biomarkers for clinic diagnosis of AMI. 
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